JPM Deep Coverage Review — Analysis as of August 3, 2026
JPMorgan’s record quarter supports the franchise case, while rates, credit and a premium valuation raise the bar for durable evidence into October.
JPMorgan’s record quarter supports the franchise case, while rates, credit and a premium valuation raise the bar for durable evidence into October.
The S&P 500 holds its intermediate trend, but energy leadership, technology weakness, and 38% watchlist breadth keep the regime mixed.
NVIDIA’s growth and margins remain exceptional, but July’s break below the 200-day average leaves customer budgets and earnings at center stage.
NVIDIA’s operating record remains exceptional, but weak technology breadth and a break below the 200-day average raise the August evidence bar.
BioViespeed fell to $20.06, while negative gross margin and a larger share count leave the recovery thesis dependent on fresh factory evidence.
BioViespeed’s lower share price does not repair negative gross margin, weak utilization or dilution risk ahead of the next operating update.
VICI raised guidance as its shares fell 3.02%; rates, funding costs and concentrated tenant exposure now put the valuation discount to a harder test.
VICI raised 2026 guidance, but tenant concentration, a 4.66% Treasury yield and the marginal cost of growth capital still define the valuation discount.
The S&P 500 is holding its intermediate trend, but Nasdaq weakness, rising rates, and 38% watchlist breadth keep the regime mixed.
WULF’s clearances matter, but the cash bridge to a second-half 2027 revenue start remains the central question.